Meeting objectives & introduction
Naval Daver & Andrew Wei

Session 1: New research perspectives in AML
Chairs: Ravi Majeti & TBC

• Immunological perspectives of long-term survivors: Paresh Vyas
• Clonal Evolution in AML: Ravi Majeti
• Predictors of transformation in CHIP and CCUS and ways to optimize prediction: Koichi Takahashi
• Potential for early intervention in CHIP and CCUS: Uma Borate
• Familial Leukemia predispositions: Understanding, identifying, and monitoring: Courtney DiNardo
• Harnessing epigenetic information in AML to identify novel potential therapeutic approaches: Maria Figueroa

Panel discussion

Break

Session 2: Controversies in AML
Chairs: Gail Roboz & Naval Daver

• Improving intensive chemotherapy approaches in frontline AML: Tapan Kadia
• Which patients should have allogeneic transplants in 2023?: Charles Craddock
• Optimal transplant conditioning regimen in AML: Betul Oran
• Intensive chemo or HMA Ven intermediate for younger AML patients?: Eunice Wang

Panel discussion

• Optimizing therapy in secondary AML and optimal use of CPX-351: Harry Erba
• Clinical approaches for IDH-mutated AML: TBC
• Current approaches for relapsed FLT3-mutant AML: Jessica Altman

Panel discussion

Session 3: New frontiers in MRD for AML clinical practice
Chairs: Richard Stone & Marina Konopleva

• Single-cell sequencing and clinical applicability in detection and therapy of AML: Catherine Smith
• Value of MRD assessment in non-intensive regimens in AML: Farhad Ravandi
• MRD as a clinical endpoint in clinical trials: Roland Walter
• Applying MRD techniques in FLT3 mutated AML – are we able to use MRD as an endpoint in FLT3 AML?: Alexander Perl
• MRD-directed interventions: Andrew Wei

Panel discussion

Lunch

Special Session: Regulatory endpoints in AML
Chairs: Courtney DiNardo & Mark Levis

• The FDA’s perspective on regulatory endpoints in AML: Joseph Wynne
• A clinical investigator’s perspective on endpoints and drug development in AML: Naval Daver

Panel discussion with Joseph Wynne, Naval Daver

Session 4: BPDCN & MDS/MPN + CMML
Chairs: Naveen Pemmaraju & TBC

• Updates in diagnosis, pathogenesis and future directions in BPDCN: Naveen Pemmaraju
• Current and new directions for accelerated/BP/transformed MPN: Anand Patel
• VEXAS: a new entity: Emma Groarke
• Future targets and drug development in CMML: Mrinal Patnaik
• Bench to bedside in MPNs: CALR and targeting CALR: Jyoti Nangalia
• Novel targeted Agents in MPNs: TBC

Panel discussion

Break

Session 5: Novel targets, combinations and treatments in AML
Chairs: Andrew Wei and Eunice Wang

Keynote talk
History of development and future directions for FLT3 inhibitors in AML: Mark Levis

New AML therapies and limitations
Chairs: Andrew Wei & Eunice Wang

• Optimizing doublet and triplet combinations in AML: improving efficacy while maintaining safety: Naval Daver
• Emerging novel antibody-drug conjugates: TBC
• Uproleselan in frontline and R/R AML: Geoffrey Uy
• TP53 treatment strategies in AML: Thomas Cluzeau

Panel discussion

• Menin inhibitors in AML: Ghayas Issa
• Mechanisms of resistance and combination approaches with Menin inhibitors in AML: Eytan Stein
• Targeting resistance to venetoclax-based therapies: Marina Konopleva
• Resistance to FLT3 inhibitors: Catherine Smith

Panel discussion

Day 1 summary

Meeting objectives & introduction
Naval Daver & Andrew Wei

Session 5, Part 2: Novel targets, combinations, and treatments in AML
What do we know about drug resistance?
Chairs: Charles Craddock and Courtney DiNardo

• Genomic landscape and prognostic implications of TP53 mutations in AML: Sanam Longhavi
• Magrolimab combinations: Naval Daver
• TP53 reactivators: David Sallman
• Novel pro-survival combinations: Andrew Wei
• When and who to transplant?: Betul Oram

Session 6: New therapies in the AML transplant setting
Chairs: Charles Craddock & TBC

• Vedolizumab for for prophylaxis and treatment of acute GVHD post alloSCT: Yngvar Fløisand
• Improving outcomes post-BMT with Iomab-B: TBC
• Cell-therapy for Epstein-Barr+ post-transplant lymphoproliferative disease: TBC
• Treating transplant-related TMA (HSCT-TMA) in AML patients: TBC
• Updates in use of post-transplant cyclophosphamide: Nelli Bejanyan

Panel discussion

Break

Session 7: Immunotherapeutics in AML
Chairs: David Sallman & John DiPersio

• Immunotherapy TME & Beyond: John DiPersio
• What Antigen should we Target in R/R AML? TBC
• Novel T-Cell Approaches for R/R AML, excluding CAR-T: Nelli Bejanyan
• NK cells & CAR NK cells: Naval Daver
• Outcomes in early-phase CAR-T clinical trials for R/R AML and MDS: David Sallman

Panel discussion

Conclusions & Meeting Close